Type 2 diabetes
Conditions
Interventions
Metformin group (additional drug therapies can be used in both groups). Metformin 500-1500mg/day will be administered for 2 months. If the patients are tolerable, the daily dose will be increased to 1
Sponsors
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences; Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients with type 2 diabetes, who understand the purpose, methods and side effect of metformin and give written informed conscent. 2. The patients with type 2 diabetes, who claim the unwanted symptoms and signs. 3. The patients with type 2 diabetes, not less than 20 years old and not more than 75 years old. 4. The patients with type 2 diabetes, who do not receive metformin.
Exclusion criteria
Exclusion criteria: 1. Lactic acidosis 2. Moderate renal dysfunction 3. Hemodialysis patients 4. Severe liver dysfunction 5. Shock, heart failure, cardiac infarction pulmonary embolism, respiratory failure, hypoxia 6. Alcohol intake 7. Dehydration, diarrhea with dehydration, vomiting 8. Severe ketosis, diabetic coma and precoma, tyep 1 diabetes 9. Severe infection, pre- and post-operation, severe trauma 10. Malnutrition, famine, panhypopituitarism and adrenal failure 11. Pregnancy 12. Allergic to biguanides
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cytokine levels of IL-2, TNFalpha, IFNgamma in CD8 T cells. | — |
Secondary
| Measure | Time frame |
|---|---|
| Expression of CTLA-4, PD-1, Tim-3 on CD4 cells (TH1, TH2, regulatory T cells), Naive T cells (CCR7+ CD45RA+), effector memory T cells (CCR7LoCD45RA-), and central memory T cells (CCR7HiCD45RA-). | — |
Countries
Japan
Contacts
Public ContactJun Wada
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Outcome results
None listed